Showing results (601-610 of 2,811) with videos related to
Sort By:
Pageof 282
Expert Opinion on Drug Safety|August 18, 2020
New and emerging cardiovascular and antihypertensive drugsSteven G Chrysant, George S ChrysantExpert Opinion on Drug Safety|April 8, 2021
Long-term efficacy and safety of botulinum toxin treatment for cervical dystonia: a critical reappraisalLuca Marsili, Matteo Bologna, Joseph Jankovic, et al.Expert Opinion on Drug Safety|August 8, 2025
Artificial intelligence in pharmacovigilance signal management: a review of tools, implementations, research, and regulatory landscapeMaria Antonietta Barbieri, Vera Battini, Carla Carnovale, et al.Expert Opinion on Drug Safety|July 16, 2025
Suspected statin-related adverse drug reactions: analysis of spontaneous reports in Hubei Province, China (2014-2022)Haochengyi Wang, Hongyu Bi, Xiaofang Shangguan, et al.Expert Opinion on Drug Safety|June 16, 2025
Risk of musculoskeletal disorders associated with Bruton's tyrosine kinase inhibitors: a disproportionality analysis of FAERS database and meta-analysisMohammed Zuber, Christy Thomas, Shifa Taj, et al.Expert Opinion on Drug Safety|June 7, 2025
Clozapine-treated patients and myocardial infarction in adults: a pharmacovigilance study in VigiBase interpreted in the context of the literatureCarlos De Las Cuevas, Emilio J Sanz, Jose de LeonExpert Opinion on Drug Safety|February 9, 2024
Renal drug dosage adjustments and adverse drug events in patients with chronic kidney disease admitted to the hospital: a cross-sectional studyZuzana Očovská, Jana Procházková, Martina Maříková, et al.Expert Opinion on Drug Safety|March 14, 2024
A real-world pharmacovigilance study of QT interval prolongation and Torsades de Pointes associated with CDK4/6 inhibitors in breast cancer patients: findings from the FDA adverse event reporting systemYu Yan, Bin Wu, Ling WangExpert Opinion on Drug Safety|April 3, 2024
Detection and analysis of signals of adverse events of memantine based on the US food and drug administration adverse event reporting systemWeichui Zhang, Mianhai Chen, Xiaolin Cai, et al.Expert Opinion on Drug Safety|July 17, 2024
Comparing musculoskeletal and connective tissue disorder risks of teriparatide and abaloparatide in osteoporosis: an analysis based on FDA adverse event reporting system (FAERS)Ming-Tao Wen, Di Luo, Jia-Cheng Li, et al.Pageof 282